Cytokinetics Stock Forecast NASDAQ:CYTK

Price Target and Analyst Ratings

Most Recent Rating

On September 07, 2021 "Barclays" gave "$40.00 - $45.00" rating for CYTK. The price target was changed from $32.46 to 3.2%.

Last 30 Days

Historical Ratings

Date	Rating	Action	Authority	Current Price	Target Price
2021-09-07	$40.00 - $45.00	Target Raised by	Barclays	$31.05	$32.46→3.2%
2021-08-09	$42.00 - $40.00	Target Lowered by	Piper Sandler	$31.89	$31.82+5.2%
2021-08-06	$53.00 - $58.00	Target Raised by	HC Wainwright	$31.82	$30.24+2.5%
2021-07-20	$35.00 - $48.00	Target Raised by	Cantor Fitzgerald	$29.18	$27.00+40.4%
2021-07-20	$28.00 - $40.00	Target Raised by	Barclays	$29.18	$27.00+40.4%
2021-07-19	$37.00 - $54.00	Target Raised by	Raymond James	$27.00	$27.20+41.4%
2021-07-19	$25.00 - $42.00	Target Raised by	Piper Sandler	$27.00	$27.20+41.4%
2021-07-19	$26.00 - $44.00	Target Raised by	JMP Securities	$27.00	$27.20+41.4%
2021-07-19	$41.00 - $53.00	Target Raised by	HC Wainwright	$27.00	$28.28+47.1%
2021-07-19	$33.00 - $48.00	Target Raised by	Needham & Company LLC	$27.00	$28.78+49.7%
2021-07-01	$36.00	Initiated by	Mizuho	$20.98	$19.59→0.7%
2021-07-01	Buy	Initiated by	Mizuho	$20.98	$36.00
2021-05-11	Buy	Target Raised by	Mizuho	$23.77	$26.00 → $36.00
2021-04-26	Overweight	Target Raised by	Morgan Stanley	$26.99	$24.00 → $35.00
2021-04-19	Overweight	Target Raised by	Morgan Stanley	$24.73	$24.00 → $35.00
2021-03-17	Outperform	Initiated by	Wolfe Research	$25.68	$50.00
2021-03-11	Outperform	Initiated by	Wolfe Research	$20.30	$50.00
2021-03-11	Outperform	Initiated by	Wolfe Research	$20.30
2021-02-18	Overweight	Initiated by	Barclays	$21.01	$28.00
2021-01-20	Buy	Target Raised by	HC Wainwright	$19.98	$22.00 → $41.00
2020-12-16	Overweight	Target Raised by	Morgan Stanley	$21.00	$22.00 → $24.00
2020-12-14	Buy	Target Lowered by	Mizuho	$21.24	$31.00 → $26.00
2020-11-24	Buy	Reiterated by	Raymond James	$16.49
2020-11-23	Buy	Target Lowered by	HC Wainwright	$16.07	$43.00 → $22.00
2020-11-16	Buy	Reiterated by	Needham & Company LLC	$15.59	$33.00
2020-11-16	Overweight	Target Lowered by	Morgan Stanley	$15.59	$24.00 → $22.00
2020-10-28	Neutral	Initiated by	The Goldman Sachs Group	$15.35	$16.00
2020-10-12	Overweight	Target Lowered by	Morgan Stanley	$15.65	$35.00 → $24.00
2020-10-08	Positive - Buy	Target Lowered by	HC Wainwright	$16.00	$59.00 → $43.00
2020-10-08	Buy	Target Lowered by	HC Wainwright	$16.00	$59.00 → $43.00
2020-10-06	Overweight	Target Raised by	Cantor Fitzgerald	$28.55	$41.00 → $48.00
2020-07-23	Buy	Target Raised by	HC Wainwright	$24.23	$38.00 → $59.00
2020-07-23	Overweight	Target Raised by	Piper Sandler	$24.23	$33.00 → $36.00
2020-07-15	Overweight	Target Raised by	Cantor Fitzgerald	$28.96	$29.00 → $41.00
2020-07-15	Outperform	Target Raised by	JMP Securities	$28.96	$23.00 → $29.00
2020-07-14	Buy	Target Raised by	HC Wainwright	$27.88	$35.00 → $38.00
2020-07-14		Target Raised by	Piper Sandler	$27.88	$28.00 → $33.00
2020-07-14	Buy	Target Raised by	Needham & Company LLC	$27.88	$34.00 → $45.00
2020-07-10	Strong-Buy	Initiated by	Raymond James	$25.50	$39.00
2020-05-12	Overweight	Target Raised by	Morgan Stanley	$20.96	$25.00 → $29.00
2020-05-11	Positive - Buy	Target Raised by	HC Wainwright	$20.99	$30.00 → $35.00
2020-05-07	Buy	Reiterated by	Needham & Company LLC	$15.73	$24.00
2020-05-04	Buy	Initiated by	Mizuho	$15.17
2020-04-27	Buy	Reiterated by	Morgan Stanley	$15.65	$25.00
2020-04-24	Buy	Reiterated by	HC Wainwright	$15.68
2020-04-19	Equal Weight - Overweight	Upgraded by	Morgan Stanley	$15.24
2020-04-17	Overweight	Target Raised by	Cantor Fitzgerald	$15.24	$12.00 → $23.00
2020-04-14	Buy	Reiterated by	Needham & Company LLC	$13.55	$24.00
2020-04-09	Equal Weight - Overweight	Upgraded by	Morgan Stanley	$13.89	$14.00 → $25.00

CYTK Stock Trend

The stock lies in the middle of a wide and strong rising trend in the short term and a further rise within the trend is signaled.

Given the current short-term trend, the stock is expected to rise 62.34% during the next 3 months and, with a 90% probability hold a price between $49.56 and $60.24 at the end of this 3-month period.

WARNING: Trend forecast is still in the development phase and should be used with caution. Some cases might produce unexpected results such as negative prices at the end of the trend.

Data

Date	Bottom	Mid	Top
2021-09-30	$30.75	$34.04	$37.33
2021-10-01	$30.98	$34.27	$37.56
2021-10-04	$31.21	$34.50	$37.78
2021-10-05	$31.43	$34.72	$38.01
2021-10-06	$31.66	$34.95	$38.24
2021-10-07	$31.88	$35.17	$38.46
2021-10-08	$32.11	$35.40	$38.69
2021-10-11	$32.34	$35.63	$38.92
2021-10-12	$32.56	$35.85	$39.14
2021-10-13	$32.79	$36.08	$39.37
2021-10-14	$33.02	$36.30	$39.59
2021-10-15	$33.24	$36.53	$39.82
2021-10-18	$33.47	$36.76	$40.05
2021-10-19	$33.69	$36.98	$40.27
2021-10-20	$33.92	$37.21	$40.50
2021-10-21	$34.15	$37.44	$40.72
2021-10-22	$34.37	$37.66	$40.95
2021-10-25	$34.60	$37.89	$41.18
2021-10-26	$34.82	$38.11	$41.40
2021-10-27	$35.05	$38.34	$41.63
2021-10-28	$35.28	$38.57	$41.86
2021-10-29	$35.50	$38.79	$42.08
2021-11-01	$35.73	$39.02	$42.31
2021-11-02	$35.96	$39.24	$42.53
2021-11-03	$36.18	$39.47	$42.76
2021-11-04	$36.41	$39.70	$42.99
2021-11-05	$36.63	$39.92	$43.21
2021-11-08	$36.86	$40.15	$43.44
2021-11-09	$37.09	$40.38	$43.66
2021-11-10	$37.31	$40.60	$43.89

About Cytokinetics

Cytokinetics, Incorporated, a late stage biopharmaceutical company, focuses on the discovery and development of novel small molecule therapeutics that modulate muscle function for the treatment of serious diseases and medical conditions. It is developing tirasemtiv, a fast skeletal muscle troponin activator that is in Phase III clinical trials for the treatment of amyotrophic lateral sclerosis; CK-2127107, which is in Phase II clinical trials for... Read more

Golden Star Signal

This unique signal uses moving averages and adds special requirements that convert the very good Golden Cross into a Golden Star.

This signal is rare and, in most cases, gives substantial returns. From 10 000+ stocks usually only a few will trigger a Golden Star Signal per day!

Get access to Golden Star list now!